World's Best Scientists 2026 revealed!
Giorgio V. Scagliotti

Giorgio V. Scagliotti

D-Index & Metrics

Medicine

D-Index
99
Citations
60372
World Ranking
8409
National Ranking
281

Overview

Giorgio V. Scagliotti is affiliated with the University of Turin in Italy and has contributed extensively to the field of medicine, with a particular focus on pulmonary and respiratory medicine, oncology, and cancer research. Their research covers a wide range of subfields including molecular biology and surgery.

Their main research topics include:

  • Lung Cancer Treatments and Mutations
  • Prostate Cancer Treatment and Research
  • Cancer Genomics and Diagnostics
  • Lung Cancer Research Studies
  • PARP inhibition in cancer therapy
  • Cancer Immunotherapy and Biomarkers
  • Lung Cancer Diagnosis and Treatment

Scagliotti has frequently published in a variety of scientific journals. The primary publication venues include:

  • Journal of Thoracic Oncology
  • Annals of Oncology
  • Clinical Lung Cancer
  • Critical Reviews in Oncology/Hematology
  • Cancer Research

Some of the recent papers authored or co-authored by Scagliotti are:

  • "The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015" (2021), Journal of Thoracic Oncology
  • "Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer" (2021), Journal of Thoracic Oncology
  • "Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial" (2020), The Lancet Oncology
  • "IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy" (2020), Journal of Thoracic Oncology
  • "Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial" (2021), The Lancet Oncology

Collaborations play a significant role in Scagliotti's work with frequent co-authors including Paolo Bironzo, Silvia Novello, Luisella Righi, Francesco Passiglia, and Massimo Di Maïo.

Best Publications

  • International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma

    William D Travis;Elisabeth Brambilla;Masayuki Noguchi;Andrew G Nicholson

  • Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

    Giorgio Vittorio Scagliotti;Purvish Parikh;Joachim von Pawel;Bonne Biesma

  • Lung cancer: current therapies and new targeted treatments

    Fred R Hirsch;Giorgio V Scagliotti;James L Mulshine;Regina Kwon

  • Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group

    Jean Pierre Pignon;Hélène Tribodet;Giorgio V. Scagliotti;Jean Yves Douillard

  • Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2

    Roy S. Herbst;Giuseppe Giaccone;Joan H. Schiller;Ronald B. Natale

  • Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1

    Giuseppe Giaccone;Roy S. Herbst;Christian Manegold;Giorgio Scagliotti

  • Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.

    Giorgio V. Scagliotti;F. De Marinis;M. Rinaldi;L. Crinò

  • Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma

    David H. Henry;Luis Costa;Francois Goldwasser;Vera Hirsh

  • The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III Studies

    Giorgio Scagliotti;Nasser Hanna;Frank V Fossella;Katherine Sugarman

  • Randomized Study of Adjuvant Chemotherapy for Completely Resected Stage I, II, or IIIA Non–Small-Cell Lung Cancer

    Giorgio V. Scagliotti;Roldano Fossati;Valter Torri;Lucio Crinò

  • The 2021 WHO Classification of Lung Tumors: Impact of advances since 2015.

    Andrew G. Nicholson;Ming S. Tsao;Mary Beth Beasley;Alain C. Borczuk

  • Prevalence of adrenal incidentaloma in a contemporary computerized tomography series

    S. Bovio;A. Cataldi;G. Reimondo;P. Sperone

  • Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC

    Christian Rolfo;Philip C. Mack;Giorgio V. Scagliotti;Paul Baas

  • Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial

    Alice T Shaw;Tae Min Kim;Lucio Crinò;Cesare Gridelli

  • Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase.

    Paolo Ceppi;Marco Volante;Silvia Saviozzi;Ida Rapa

  • Phase III Study of Carboplatin and Paclitaxel Alone or With Sorafenib in Advanced Non–Small-Cell Lung Cancer

    Giorgio Scagliotti;Silvia Novello;Joachim von Pawel;Martin Reck

  • ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine

    P. Ceppi;M. Volante;S. Novello;I. Rapa

  • Gemcitabine and Cisplatin Versus Mitomycin, Ifosfamide, and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Randomized Phase III Study of the Italian Lung Cancer Project

    L. Crinò;Giorgio V. Scagliotti;S. Ricci;F. De Marinis

  • Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study.

    L Crino;G V Scagliotti;M Marangolo;F Figoli

  • Pretreatment Quality of Life and Functional Status Assessment Significantly Predict Survival of Elderly Patients With Advanced Non—Small-Cell Lung Cancer Receiving Chemotherapy: A Prognostic Analysis of the Multicenter Italian Lung Cancer in the Elderly Study

    Paolo Maione;Francesco Perrone;Ciro Gallo;Luigi Manzione

Frequent Co-Authors

Silvia Novello
Silvia Novello University of Turin
Mauro Papotti
Mauro Papotti University of Turin
Rafael Rosell
Rafael Rosell Autonomous University of Barcelona
Alfredo Berruti
Alfredo Berruti University of Brescia
Martin Reck
Martin Reck LungenClinic Grosshansdorf
Filippo De Marinis
Filippo De Marinis European Institute of Oncology
David R. Spigel
David R. Spigel Sarah Cannon Research Institute
Joachim von Pawel
Joachim von Pawel The University of Texas MD Anderson Cancer Center
Keunchil Park
Keunchil Park The University of Texas MD Anderson Cancer Center
Frances A. Shepherd
Frances A. Shepherd Princess Margaret Cancer Centre

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring online degrees is a flexible and cost-effective way for students to advance in the medical field. Many choose nursing as a starting point, with several accredited and accessible programs available throughout the USA. For those aiming to minimize expenses while gaining a high-level qualification, researching the cheapest dnp online program can provide an affordable pathway to leadership roles.

Registered Nurses (RNs) may consider transitioning to a Bachelor of Science in Nursing (BSN) for better career prospects. However, it's important to weigh the average cost of rn to bsn programs to ensure the investment fits your budget.

Non-nursing graduates interested in healthcare can take accelerated routes to qualify as nurses. For example, specific schools offer a non nursing bachelor's to msn online program, allowing career changers to fast-track their nursing education.

Additionally, individuals without a nursing background may find online bsn programs for non nurses that offer flexible coursework and admissions criteria, broadening access to the profession.

Best Scientists Citing Giorgio V. Scagliotti

Trending Scientists